MG
VKTX icon

Marex Group’s Viking Therapeutics VKTX Stock Holding History

Marex Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Buy
46,654
+14,343
+44% +$463K 0.01% 391
2026
Q1 		$1.05M Sell
32,311
-4,116
-11% -$132K 0.01% 427
2025
Q4 		$1.28M Sell
36,427
-2,813
-7% -$99.7K 0.01% 372
2025
Q3 		$1.03M Buy
39,240
+2,136
+6% +$63.7K 0.01% 351
2025
Q2 		$983K Buy
37,104
+20,390
+122% +$537K 0.01% 290
2025
Q1 		$404K Buy
+16,714
New +$528K 0.01% 384
2024
Q2 		– Sell
-4,442
Closed -$364K – 726
2024
Q1 		$364K Buy
+4,442
New +$198K 0.01% 300

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marex Group's VKTX Position: Q2 2026 in Review

Marex Group increased its Viking Therapeutics (VKTX) stake by 44% in Q2 2026, buying an estimated $463K and bringing the position to 46,654 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #391.

Marex Group first reported a position in VKTX in Q1 2024 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Marex Group held 46,654 shares of Viking Therapeutics worth $1.82M as of Q2 2026.
  • Marex Group bought 14,343 Viking Therapeutics shares in Q2 2026, an estimated $463K.
  • Viking Therapeutics made up 0.01% of Marex Group's portfolio in Q2 2026, its #391 holding.
  • Marex Group first reported a position in Viking Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.